Conecte-se

Bibliografias temáticas / Cancer drug resistance, tumor metabolism / Livros

Siga este link para ver outros tipos de publicações sobre o tema: Cancer drug resistance, tumor metabolism.

Livros sobre o tema "Cancer drug resistance, tumor metabolism"

Autor: Grafiati

Publicado: 14 de março de 2023

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 25 melhores livros para estudos sobre o assunto "Cancer drug resistance, tumor metabolism".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

Dr, Mehta Kapil, e Siddik Zahid H, eds. Drug resistance in cancer cells. New York, NY: Springer, 2009.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Benjamin, Bonavida, ed. Sensitization of cancer cells for chemo/immuno/radio-therapy. Totowa, NJ: Humana Press, 2008.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

S, El-Deiry Wafik, ed. Tumor progression and therapeutic resistance. New York, NY: New York Academy of Sciences, 2005.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

B, Roninson Igor, ed. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum Press, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Lauricella, Marianna, e Sonia Emanuele. Novel apoptotic drugs in targeting tumor cells. Trivandrum, Kerala, India: Researh Signpost, 2007.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Kim, Kŏn-hong. Yubangam ŭi taje yangmul naesŏng saengchʻe chipʻyo palgul mit kŭ yuyongsŏng kŏmjŭng =: Identification of biomarkers for multidrug resistance and validation of markers in breast cancer tissue. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Bonavida, Benjamin. Chemo-immunosensitization of resistant tumor cells to cell death by apoptosis, 2006. Trivandrum: Transworld Research Network, 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Julia, Gee, Nicholson Robert I e SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Dordrecht: Springer Netherlands, 2009.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

1940-, Tabuchi K., ed. Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Tokyo: Springer-Verlag, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Gregory, Bock, Goode Jamie, Novartis Foundation e Symposium on Mechanisms of Drug Resistance in Epilepsy : Lessons from Oncology (2001 : London, England), eds. Mechanisms of drug resistance in epilepsy: Lessons from oncology. Chichester, England: Wiley, 2002.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Bates, Susan E., Kapil Mehta e Zahid H. Siddik. Drug Resistance in Cancer Cells. Springer, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Bonavida, Benjamin. Sensitization of Cancer Cells for Chemo/Immuno/Radio-Therapy. Humana Press, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Gonzalez-Perez, Ruben R., e Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Gonzalez-Perez, Ruben R., e Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Gonzalez-Perez, Ruben R. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Gonzalez-Perez, Ruben R., e Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Pacak, Karel, e INTERNATIONAL SYMPOSIUM ON CATECHOLAMINE. Tumor Progression and Therapeutic Resistance (TPR) (Annals of the New York Academy of Sciences). New York Academy of Sciences, 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Hiscox, Stephen, Julia Gee e Robert I. Nicholson. Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Hiscox Stephen Gee Julia Nicholson Robert I, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Springer-Verlag, 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Multidrug resistance in cancer cells: Molecular, biochemical, physiological, and biological aspects. Chichester: J. Wiley, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

(Editor), Sudhir Gupta, e Takashi Tsuruo (Editor), eds. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Tsuruo, Takashi, e Sudhir Gupta. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley & Sons, Incorporated, John, 2007.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Texto completo da fonte

Resumo:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Josephs, Debra H., Heather J. Bax, Giulia Pellizzari, James F. Spicer, Ana Montes e Sophia N. Karagiannis. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0001.

Texto completo da fonte

Resumo:

Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular targets expressed on tumors or within tumor microenvironments that may be essential for tumor cell survival and proliferation. Recently, antibodies targeting checkpoint molecules on immune cells have shown efficacy in modulating anti-tumor immunity, and applications in ovarian carcinomas are evaluated. The chapter focuses on therapeutic agents’ attributes on targeting key cancer growth and progression pathways, and propensity to engender effector functions by activating immune effector cells in tumors and the circulation.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!